Welcome to our dedicated page for Annovis Bio news (Ticker: ANVS), a resource for investors and traders seeking the latest updates and insights on Annovis Bio stock.
Annovis Bio, Inc. (NYSE: ANVS) generates a steady flow of news as a late-stage clinical drug platform company focused on neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD). This news page aggregates announcements that reflect the company’s progress in clinical development, regulatory interactions, scientific presentations, and corporate activity.
Readers can follow updates on buntanetap, Annovis’ lead drug candidate, across multiple indications. News items include milestones from the pivotal Phase 3 trial in early Alzheimer’s disease, such as activation of clinical sites, enrollment status, and timing of key readouts. In Parkinson’s disease, press releases cover Phase 3 data analyses, biomarker findings related to amyloid co‑pathology and tau measures, and the design and objectives of the Open-Label Extension study that evaluates long-term safety and efficacy in diverse patient cohorts, including those receiving deep brain stimulation.
Company news also highlights regulatory developments, including scheduled FDA meetings to discuss the pathway for Parkinson’s disease dementia and confirmation of alignment on Phase 3 Alzheimer’s study design and endpoints. Scientific communications feature presentations at major conferences focused on Parkinson’s disease and Alzheimer’s clinical trials, where Annovis shares biomarker data, cross-study comparisons, and analyses of cognitive outcomes in patients with defined biomarker profiles.
In addition to clinical and scientific updates, this feed includes corporate events such as earnings releases, capital raises through registered direct offerings, leadership changes, and NYSE listing compliance disclosures. Investors, clinicians, and other stakeholders can use this page to track how Annovis communicates its trial progress, financial condition, and strategic priorities over time. For those following ANVS stock or the development of buntanetap in Alzheimer’s and Parkinson’s disease, this news stream provides a consolidated view of the company’s publicly reported milestones.
Annovis Bio (NYSE: ANVS), a late-stage clinical drug platform company focused on neurodegenerative disorders, has appointed Hui Liu as Director of Biostatistics. This strategic hire comes as the company advances its pivotal Phase 3 Alzheimer's disease trial.
Ms. Liu brings over 19 years of experience in clinical trial statistics, specializing in:
- Design and analysis of all clinical trial phases
- Statistical methodology expertise
- Development of statistical analysis plans
- Management of high-performing teams
According to Dr. Cheng Fang, Senior VP of Research and Development, Liu's appointment strengthens the company's scientific excellence and will support data integrity for regulatory submissions. The new Director expressed enthusiasm about joining Annovis's team and contributing to their clinical trials' quality evidence generation.
Annovis Bio (NYSE: ANVS) has received a notice from the NYSE on March 26, 2025, indicating non-compliance with continued listing standards. The company's average global market capitalization over 30 trading days fell below $50 million (approximately $37.9 million as of March 25, 2025), while stockholders' equity was $9.3 million as of December 31, 2024.
The company must submit a compliance plan within 45 days, demonstrating its ability to meet NYSE standards within 18 months. During this period, ANVS stock will continue trading with a '.BC' designation. If the plan is accepted, quarterly reviews will ensure compliance. Failure to meet requirements could result in NYSE delisting.
Annovis Bio (NYSE: ANVS) announced its participation in the AD/PD™ 2025 conference taking place April 1-5 in Vienna, where they will present comprehensive data from their latest clinical trials.
The company will deliver two key presentations: one focusing on buntanetap's improvements in cognition and motor functions in Phase 3 Parkinson's disease study, and another examining the drug's advantages for APOE4 carriers in Phase 2/3 Alzheimer's disease trials. Additionally, CEO Maria Maccecchini will participate in a forum discussion about novel approaches to biomarkers, imaging, and therapy development.
The presentations schedule includes:
- April 1, 2:45 PM CET: Buntanetap's impact on early Parkinson's patients
- April 2, 9:40 AM CET: APOE4 and buntanetap in Alzheimer's patients
- April 4, 4:20 PM CET: Forum on novel approaches in PD, LBD and MSA pathologies
Annovis Bio (NYSE: ANVS) reported its Q4 and FY 2024 financial results, highlighting significant clinical progress in their buntanetap program. The company successfully completed two clinical trials - Phase 2/3 Alzheimer's Disease (AD) and Phase 3 Parkinson's Disease (PD), with promising results in improving cognition and motor function.
Financial highlights include:
- Q4 2024 R&D expenses decreased to $5.0M from $8.9M in Q4 2023
- Q4 2024 net loss per share improved to $0.43 from $2.24 year-over-year
- FY 2024 R&D expenses reduced to $20.0M from $38.8M in 2023
- Cash position of $10.6M as of December 31, 2024
- Completed $21.0M stock offering with ThinkEquity
The FDA cleared Annovis to proceed with a pivotal Phase 3 trial in early AD, launched in early 2025. The study includes a 6-month symptomatic data readout expected in mid-2026 and disease-modifying data in mid-2027, both supporting potential New Drug Applications.
Annovis Bio (NYSE: ANVS) announced its participation in the 13th Alzheimer's & Parkinson's Drug Development Summit in Boston, MA, from March 18-20, 2025. The company's Founder and CEO, Maria Maccecchini, Ph.D., will present Phase III buntanetap data and participate in a panel discussion on March 19.
The presentation at 3:30pm EST will focus on buntanetap's clinical trial results and advocate for a holistic approach to treating neurodegenerative diseases. At 4:30pm EST, Dr. Maccecchini will join a panel exploring opportunities in alpha-synuclein and future developments in Parkinson's drug development.
The company emphasizes the need to move beyond single-protein targeting approaches, highlighting their strategy of addressing multiple neurotoxic proteins in treating conditions like Alzheimer's and Parkinson's disease.
Annovis Bio (NYSE: ANVS), a clinical-stage drug platform company focused on neurodegenerative diseases, announces a live webcast Patients' Forum scheduled for February 27, 2025, at 4:30 PM EST. CEO Maria Maccecchini, Ph.D., will lead the session, addressing questions from patients, caregivers, and families.
The forum will provide updates on several key areas including:
- Ongoing Phase 3 Alzheimer's disease trial
- Plans for Phase 3 Parkinson's disease study
- Open Label Extension studies
- Patient communication strategies
The event will feature a presentation of recent achievements followed by a Q&A session. Participants can submit questions in advance to clinicaltrials@annovisbio.com. While open to all, the forum is specifically designed for patients, families, and caregivers, demonstrating Annovis's commitment to transparency and patient-centered communication.
Annovis Bio (NYSE: ANVS) has announced its participation in Oppenheimer's 35th Annual Healthcare Life Sciences Conference. CEO Maria Maccecchini, Ph.D., will deliver a presentation on February 11, 2025, from 12:40 to 1:10 p.m. ET through the conference's virtual platform.
The presentation will focus on the company's recent developments, particularly highlighting progress in their pivotal Phase 3 trial for early Alzheimer's disease. Dr. Maccecchini will also discuss strategic initiatives regarding a New Drug Application (NDA) for buntanetap, which is being developed as both a symptomatic and potentially disease-modifying treatment.
The conference is a significant industry event that connects leading healthcare and life sciences companies with investors, offering a platform for executives to share insights on industry trends, innovations, and investment opportunities.